This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Board of Directors has decided to appoint Christopher von Jako, Ph.D., as President and Chief Executive Officer (CEO). Dr. von Jako’s appointment cements the Board’s commitment to a strategic transition to U.S.-based leadership, and will become effective in January 2020.
“Dr. von Jako is a science-driven senior executive with over 25 years of experience managing businesses and leading global medical technology companies,” said Dr. David Zacut, a co-founder of BrainsWay and Chairman of the Board, who has been serving as Interim CEO since September 2019. “Most importantly, he has significant expertise in developing and commercializing minimally-invasive medical technologies aimed at improving patient experiences and outcomes. We are highly confident that Dr. von Jako is well-suited to lead BrainsWay into its next phase of growth,” said Dr. Zacut.
“I am incredibly honored and grateful to the Board for the opportunity to lead this exceptional organization,” said Dr. von Jako. “BrainsWay has done an excellent job of developing and obtaining regulatory clearances for its innovative Deep Transcranial Magnetic Stimulation system (Deep TMS) in multiple large indications. Market demand for Deep TMS continues to grow, and I look forward to working with the management team and the Board to further accelerate BrainsWay’s commercialization and market adoption efforts in the U.S. and around the globe.”
Most recently, Dr. von Jako served as CEO of Dynatronics Corporation, a publicly-traded medical device company that designs, manufactures, and sells high-quality restorative products. Prior to Dynatronics, he served as President and CEO of NinePoint Medical, Inc., a privately-held, advanced image guidance company. Additionally, Dr. von Jako served as President and CEO of NeuroTherm, Inc., a privately-held, minimally invasive interventional pain management company. Earlier in his career, he held increasingly senior roles with other leading medical device companies, including Integra LifeSciences, Covidien, Medtronic, and Radionics.
Dr. von Jako holds a Ph.D. in Biomedical Sciences from the University of Pécs, a M.S. degree in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology, and a double B.S. degree in Physics and Mathematics from Bates College. He continues to serve as an independent director on the boards of NinePoint Medical, Inc. and nView medical Inc.
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting and/or planning clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders.